MedTrace Logo

ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome

NCT00489333 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2007-06-21

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of supplementation with ProAlgaZyme (a novel fermentation product of a freshwater algae ecosystem) vs. placebo on Metabolic Syndrome and indicators of cardiovascular health including: body weight and fat, blood lipids, inflammatory markers such as hsCRP, blood pressure and fasting blood glucose.

Conditions

  • Metabolic Syndrome X

Interventions

DRUG

ProAlgaZyme

Sponsors & Collaborators

  • University of Yaounde

    collaborator OTHER

  • Health Enhancement Products, Inc.

    lead INDUSTRY

Principal Investigators

  • Julius Oben, Ph.D. · Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2006-09-30

Countries

  • Cameroon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489333 on ClinicalTrials.gov